“From just a regular business sense, we can’t raise prices to offset some of our supply cost problems,” says David Morris, MD.
At the LUGPA 2022 Annual Meeting, David Morris, MD, Urology Associates, Nashville, TN, discussed challenges facing urology practices in an interview with Urology Times. In this video, he focuses on the difficulties urology practices have faced amid the ongoing inflation crisis.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.